New options for testing and treating some of the most common sexually transmitted diseases are becoming available. In the ...

The pathogen that causes the sexually transmitted disease gonorrhea is notorious for its ability to develop drug resistance. But now there are two more treatment options. In December, the U.S. Food ...

The FDA approved gepotidacin (Blujepa), an oral option for the treatment of uncomplicated urogenital gonorrhea among patients ages 12 years and older, GSK announced on Thursday. "The ability of N.

At a time when Americans' trust in public health agencies are waining, Sen. Ron Johnson, R-Wisconsin, is under fire for promoting a book peddling an unfounded medical theory that bleaching can treat ...

(RTTNews) - Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (INVA), announced that the U.S. Food and Drug Administration approved NUZOLVENCE (zoliflodacin) for oral suspension, a first ...

FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against Neisseria gonorrhoeae infection in regions with a high prevalence of gonorrhea ...

WALTHAM, Mass. - The U.S. Food and Drug Administration has approved NUZOLVENCE (zoliflodacin), a first-in-class, single-dose oral medication for treating uncomplicated urogenital gonorrhea in adults ...

After a three-decade drought of new antibiotics to treat gonorrhea, the FDA has signed off on two first-in-class oral treatments for the sexually transmitted infection (STI), which affects more than ...

On Thursday, ProPublica reported that Senator Ron Johnson (R-WI) is endorsing a forthcoming book that promotes chlorine dioxide — a chemical commonly used for disinfecting and bleaching — as a ...

With an increase in the antimicrobial resistance to therapies for gonorrhea, doctors have been left with fewer options to treat the sexually transmitted infection (STI), which strikes more an 80 ...

Please provide your email address to receive an email when new articles are posted on . Gonorrhea has become increasingly resistant to existing antibiotics. Two newly approved drugs, gepotidacin and ...

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced the publication of positive results from a pivotal Phase 3 trial ...